In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. - Wikidata - thesis-toulmin - TriplyDB

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

http://www.wikidata.org/entity/Q43803587

about

PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty Gene expression microarray analysis of the sciatic nerve of mice with diabetic neuropathy.Potential of 3,4-dihydroxy-phenyl lactic acid for ameliorating ischemia-reperfusion-induced microvascular disturbance in rat mesentery.Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice Minireview: Challenges and opportunities in development of PPAR agonists Cardiac remodeling in obesity.Induction of PGC-1α expression can be detected in blood samples of patients with ST-segment elevation acute myocardial infarction Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation.Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly Involvement of PPAR nuclear receptors in tissue injury and wound repair Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor γ.Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes.Reconstituted high-density lipoprotein modulates activation of human leukocytes.Thiazolidinediones -- some recent developments.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.Peroxisome proliferator-activated receptors and cardiovascular remodeling.Peroxisome proliferator-activated receptor ligands in atherosclerosis.Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside PGC-1α induction in pulmonary arterial hypertension Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Fibroblast Growth Factor-9 Activates c-Kit Progenitor Cells and Enhances Angiogenesis in the Infarcted Diabetic Heart.The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.Protective effect of pioglitazone on cardiomyocyte apoptosis in low-dose streptozotocin & high-fat diet-induced type-2 diabetes in rats Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism Targeting the mitochondria to augment myocardial protection.Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism.Previous exercise training increases levels of PPAR-α in long-term post-myocardial infarction in rats, which is correlated with better inflammatory response Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.Cyclic Stretch Facilitates Myogenesis in C2C12 Myoblasts and Rescues Thiazolidinedione-Inhibited Myotube Formation.Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs.PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation.

P2860

Q27024799-1DB7CD03-AB55-43EE-8162-3572EBCBF0BB Q30369017-96B1BB95-FFDF-43C5-B084-6485B007072F Q33384371-61F4850B-ED61-44FF-94D7-C23F6E1342D5 Q33442332-DE702E26-DF74-419E-99D3-B0631E62DE66 Q33631921-660D8B19-2185-44EB-8575-32AB5E9A6E64 Q34043589-87E37968-D928-4DA2-8A93-BABDBD77790E Q34075457-8FEFA966-1887-4008-9140-5C0741887C6F Q34086987-D6F1E10A-42A6-43DA-980B-6B201567AF7E Q34259900-22635C9D-63D4-4D5A-9355-13605E11F598 Q34386587-EB328857-8CA8-4921-A05D-DF1C8CFA427F Q34416422-C11DE02F-5AA5-4B71-B477-667A2372C835 Q34576530-77C2A02A-380A-4747-A24B-6D3978D59C0C Q34759513-46B3E6E4-B2EC-4346-8030-5CF542633237 Q34805939-E4EBCAD2-54CD-4B83-B2CE-7B6AA6FF095B Q34963571-DFC7662B-9B96-4CD2-98BA-EEB106D79E7B Q35164761-7CCE8E66-AF14-4BAE-802A-12577B24136D Q35688221-798F8291-7CD7-4531-BDC6-DF2F351C962B Q35750111-D9A44D07-7387-49DD-89E4-1256FD390DAB Q35890826-B9A043AE-E083-4A1F-8149-F4702022C477 Q35925566-4823682E-6B84-4B5B-AC7F-00BEFDF26CC2 Q36056207-83E8BB39-0797-419F-A132-7B769863C8C0 Q36221045-EEFA924D-B47A-4A03-9D28-AB4861A2FFE2 Q36261125-094D87EF-CE72-4132-9E41-ACEB8CA75B24 Q36320556-A3635F63-E3E6-4B98-B657-FDD58BF905C1 Q36349188-7B2F24EE-0487-4624-A115-01969CA957C2 Q36445381-56069DFD-8753-4193-AB58-D77FAAC29A92 Q36550203-67CDABA2-4DF8-4228-B1AA-DB840B93E91E Q36555556-F17E3712-6C21-4FFC-A6C2-29EA916E667D Q36613672-A37116B9-3DBB-492D-A08D-67E9548F1395 Q36632030-6A3D65DF-4ADB-4D63-9981-B90A2B13A6AC Q36672160-FDFE3679-281D-4F8A-A656-76615CB530CE Q36689230-6E24AE73-9B24-4E62-A857-CDBC0407C9CF Q36707537-BF74226C-8B08-41F7-842C-2D484476970C Q36787381-0C18EDE4-A4F7-43D2-8671-D2908CE69B65 Q36787467-7A5C1446-86FC-4CD6-BE4E-BFAB6AE8B160 Q36787677-B0E5156E-6F11-4491-B746-1C2470F95E28 Q36952106-406D034A-ECC6-4E60-8466-5818E5939DD7 Q37107490-32C7E335-7645-45C2-96D0-61C9DDC21C7D Q37362740-6F96897C-4029-4C17-9900-E79CC302543A Q37786549-2291A1A4-3F30-45D7-B4C7-1E8FC46D2A36

P2860

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

http://www.wikidata.org/entity/Q43803587

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@en

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@nl

type

label

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@en

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@nl

prefLabel

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@en

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@nl

P1433

Q43803587-A13BF8AD-9C97-4893-A0A5-FBA9B77812CB

P1476

Q43803587-3B0B20EB-E34F-413D-84CE-9A4E19654891

P2093

Q43803587-094B539D-F02E-4996-B100-14114468CD30

Q43803587-1A5D5DE1-D136-484C-9CB9-022A86515620

Q43803587-4D89F1CC-AA0B-40BC-A32E-1785FB0FB996

Q43803587-67C8576B-3797-4DE0-925E-0EC04A7D7073

Q43803587-72ED7098-F4AE-4804-A1C1-3BE0611FA807

Q43803587-B094902A-24B6-4893-B4D1-1B67D8A445B5

Q43803587-BFB9E3C1-8DE8-446F-B6A0-EB04C0232C97

Q43803587-C0823772-76FD-4636-ABB5-F833F2E7C6BA

Q43803587-C186D6E5-6EFB-4243-A754-60ABA5EEEB99

Q43803587-D08CA6E5-997C-4619-84C4-1DC41B57E428

P304

Q43803587-C1BEDE4F-1457-43BC-8410-7B37FCA573E8

P31

Q43803587-D44E167B-4247-4A22-89FF-ED33FBE124E3

P356

Q43803587-BBCF1361-2974-400F-B390-2037EB45B45F

P407

Q43803587-ADB9BEBA-A875-4FE5-B330-8DBFDCDDED97

P433

Q43803587-5DBB6159-AA42-4C3F-BDDF-E1C97B546B82

P478

Q43803587-C232C4E9-407E-433A-AF6E-052BBFABAA75

P577

Q43803587-2BDA4EBE-3210-4952-8368-64AFFAF40483

P5875

Q43803587-3765D18C-E76F-4A15-99EA-FF4880F8937D

P698

Q43803587-31406098-F129-4737-ABB7-2B1E4C867E56

P921

Q43803587-F913F45F-FD19-44E9-AF4E-7D19F883D590

P356

P1433

P1476

In vivo myocardial protection ...... r-gamma agonist rosiglitazone.

@en

P2093

Bao W

http://www.w3.org/2001/XMLSchema#string

Boyce R

http://www.w3.org/2001/XMLSchema#string

Bril A

http://www.w3.org/2001/XMLSchema#string

Buckingham RE

http://www.w3.org/2001/XMLSchema#string

Chen J

http://www.w3.org/2001/XMLSchema#string

Gu JL

http://www.w3.org/2001/XMLSchema#string

Hart TK

http://www.w3.org/2001/XMLSchema#string

Jiang W

http://www.w3.org/2001/XMLSchema#string

Lysko PG

http://www.w3.org/2001/XMLSchema#string

Narayanan PK

http://www.w3.org/2001/XMLSchema#string

P304

2588-2594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HC4601.099403

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11640010

http://www.w3.org/2001/XMLSchema#string

P698

11714655

http://www.w3.org/2001/XMLSchema#string

P921

reperfusion injury